The stock of Cns Pharmaceuticals Inc (CNSP) has seen a -10.41% decrease in the past week, with a -6.15% drop in the past month, and a -32.73% decrease in the past quarter. The volatility ratio for the week is 13.35%, and the volatility levels for the past 30 days are at 22.38% for CNSP. The simple moving average for the last 20 days is -7.66% for CNSP’s stock, with a simple moving average of -98.13% for the last 200 days.
Is It Worth Investing in Cns Pharmaceuticals Inc (NASDAQ: CNSP) Right Now?
The 36-month beta value for CNSP is at 1.05. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CNSP is 36.55M, and currently, shorts hold a 3.11% of that float. The average trading volume for CNSP on November 18, 2024 was 14.13M shares.
CNSP) stock’s latest price update
Cns Pharmaceuticals Inc (NASDAQ: CNSP)’s stock price has soared by 8.94 in relation to previous closing price of 0.11. Nevertheless, the company has seen a loss of -10.41% in its stock price over the last five trading days. accesswire.com reported 2024-11-18 that HOUSTON, TX / ACCESSWIRE / November 18, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its abstract has been selected for poster presentation at the 29th Annual Meeting of the Society for Neuro-Oncology being held November 21-24, 2024 in Houston, TX. Details of the presentation are as follows: Title: Update on a Potentially Pivotal Trial CNS-201: A Randomized, Controlled Trial of Berubicin Vs.
Analysts’ Opinion of CNSP
Ladenburg Thalmann, on the other hand, stated in their research note that they expect to see CNSP reach a price target of $11. The rating they have provided for CNSP stocks is “Buy” according to the report published on August 24th, 2020.
CNSP Trading at -12.30% from the 50-Day Moving Average
After a stumble in the market that brought CNSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.92% of loss for the given period.
Volatility was left at 22.38%, however, over the last 30 days, the volatility rate increased by 13.35%, as shares sank -18.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.20% lower at present.
During the last 5 trading sessions, CNSP fell by -6.89%, which changed the moving average for the period of 200-days by -99.05% in comparison to the 20-day moving average, which settled at $0.1242. In addition, Cns Pharmaceuticals Inc saw -99.82% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CNSP starting from Gumulka Jerzy, who purchase 33,333 shares at the price of $0.30 back on Feb 01 ’24. After this action, Gumulka Jerzy now owns 43,006 shares of Cns Pharmaceuticals Inc, valued at $10,000 using the latest closing price.
Evans Carl Anthony, the Director of Cns Pharmaceuticals Inc, purchase 33,333 shares at $0.30 during a trade that took place back on Feb 01 ’24, which means that Evans Carl Anthony is holding 33,458 shares at $10,000 based on the most recent closing price.
Stock Fundamentals for CNSP
Current profitability levels for the company are sitting at:
- -2684.89 for the present operating margin
- 0.6 for the gross margin
The net margin for Cns Pharmaceuticals Inc stands at -2681.03. The total capital return value is set at -5.1. Equity return is now at value -2116.75, with -350.34 for asset returns.
Based on Cns Pharmaceuticals Inc (CNSP), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -454.64. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -1458.57.
Currently, EBITDA for the company is -18.86 million with net debt to EBITDA at 0.41. When we switch over and look at the enterprise to sales, we see a ratio of -50.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.81.
Conclusion
In conclusion, Cns Pharmaceuticals Inc (CNSP) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
